Literature DB >> 9718634

A review of longitudinal studies of cognitive functions in schizophrenia patients.

B R Rund1.   

Abstract

Even though the idea that schizophrenia is a neurobehavioral syndrome has become a mainstream position, there is no consensus on the precise nature of the cognitive and neuropsychological impairment. Research on cognitive dysfunctions in schizophrenia has been directed toward discriminating stable dysfunctions (traits) from symptom-linked (state) deficits. A longitudinal study design is the only one that can provide answers to the question of the stability of psychological functions. This article reviews 15 studies with a followup of at least a year. The main conclusion drawn from these studies is that after the onset of schizophrenia, cognitive deficits are relatively stable over long periods. No support for a decline in cognitive functions is found. Thus, schizophrenia does not appear to be a degenerative process, but rather a static encephalopathy. Whether or not the cognitive deficits found in schizophrenia can be remediated is still an open question that needs to be examined.

Entities:  

Mesh:

Year:  1998        PMID: 9718634     DOI: 10.1093/oxfordjournals.schbul.a033337

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  66 in total

1.  Neurocognition in schizophrenia: a 20-year multi-follow-up of the course of processing speed and stored knowledge.

Authors:  Aaron Bonner-Jackson; Linda S Grossman; Martin Harrow; Cherise Rosen
Journal:  Compr Psychiatry       Date:  2010-03-29       Impact factor: 3.735

2.  Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia.

Authors:  Xiang Yang Zhang; Jun Liang; Da Chun Chen; Mei Hong Xiu; Fu De Yang; Therese A Kosten; Thomas R Kosten
Journal:  Psychopharmacology (Berl)       Date:  2012-01-26       Impact factor: 4.530

3.  Cognitive predictors of social functioning improvements following cognitive remediation for schizophrenia.

Authors:  Clare Reeder; Nicola Smedley; Kate Butt; Diana Bogner; Til Wykes
Journal:  Schizophr Bull       Date:  2006-08-10       Impact factor: 9.306

Review 4.  Schizopsychotic symptom-profiles and biomarkers: beacons in diagnostic labyrinths.

Authors:  Tomas Palomo; Richard M Kostrzewa; Richard J Beninger; Trevor Archer
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

5.  The stability of inhibitory and working memory deficits in children and adolescents who are children of parents with schizophrenia.

Authors:  Randal G Ross; Brandie Wagner; Shari Heinlein; Gary O Zerbe
Journal:  Schizophr Bull       Date:  2007-09-14       Impact factor: 9.306

6.  Cognition in young schizophrenia outpatients: comparison of first-episode with multiepisode patients.

Authors:  Yoram Braw; Yuval Bloch; Shlomo Mendelovich; Gideon Ratzoni; Gilad Gal; Hagai Harari; Asaf Tripto; Yechiel Levkovitz
Journal:  Schizophr Bull       Date:  2007-11-05       Impact factor: 9.306

Review 7.  Cognitive impairment in schizophrenia and affective psychoses: implications for DSM-V criteria and beyond.

Authors:  Emre Bora; Murat Yücel; Christos Pantelis
Journal:  Schizophr Bull       Date:  2009-09-23       Impact factor: 9.306

8.  Right-hemisphere encephalopathy in elderly subjects with schizophrenia: evidence from neuropsychological and brain imaging studies.

Authors:  V S Gabrovska-Johnson; M Scott; S Jeffries; N Thacker; R C Baldwin; A Burns; S W Lewis; J F W Deakin
Journal:  Psychopharmacology (Berl)       Date:  2003-07-04       Impact factor: 4.530

9.  Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia.

Authors:  Tonmoy Sharma; Catherine Hughes; William Soni; Veena Kumari
Journal:  Psychopharmacology (Berl)       Date:  2003-07-04       Impact factor: 4.530

10.  Neuropsychological impairments predict the clinical course in schizophrenia.

Authors:  Wolfgang Wölwer; Jürgen Brinkmeyer; Mathias Riesbeck; Lena Freimüller; Ansgar Klimke; Michael Wagner; Hans-Jürgen Möller; Stefan Klingberg; Wolfgang Gaebel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-11       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.